Cabot Corporation
NYSE:CBTChemicals - Specialty
+$0.96 today
- Market cap
- $3.80B
- Beta
- 0.83
- P/E (TTM)
- 16.3
- EPS (TTM)
- $5.48
- Dividend yield
- 2.04%
Volume 0.53M
Average 0.43M
CBT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Cabot CorporationNYSE: CBT
Depreciation & Amortization · Q3 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $50M rose 28.2% year over year, ahead of the +19.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +1.8% a year.
Context
- Depreciation & amortization amounted to 4.1% of revenue in FY2025, up 0.4 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +28.2% holds above the trailing-twelve-month pace of +19.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 154M USD
- Year-over-year change
- +2.0%
- 4-year CAGR
- -1.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 154M | +2.0% |
| FY2024 | 2024-09-30 | 151M | +4.9% |
| FY2023 | 2023-09-30 | 144M | -1.4% |
| FY2022 | 2022-09-30 | 146M | -8.8% |
| FY2021 | 2021-09-30 | 160M | — |
Depreciation & Amortization vs competitors
How CBT compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +19.2% is the 5th highest of 11, against a peer median of +13.4%.
- Depreciation & amortization amounts to 5.0% of revenue for CBT, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2026 | ZAR 13.32B ZAR | -4.9% | -8.5% | 5.0% | |
| LTM Jun 2026 | $842M USD | +7.7% | +18.0% | 8.7% | |
| LTM Jun 2026 | $478.09M USD | +20.1% | +6.2% | 11.2% | |
| LTM Jun 2026 | $213.28M USD | +34.0% | +18.0% | 6.4% | |
| LTM Sep 2026 | $191M USD | +3.7% | +4.5% | 5.6% | |
| LTM Jun 2026 | $180M USD | +19.2% | +1.8% | 5.0% | |
| LTM Aug 2026 | $138.46M USD | -22.6% | +6.7% | 3.9% | |
| LTM Jun 2026 | $80.68M USD | +19.1% | +4.0% | 10.7% | |
| LTM Jun 2026 | $62.19M USD | +2.1% | +5.2% | 3.7% | |
| LTM Sep 2026 | $55.23M USD | +19.4% | +24.2% | 4.8% | |
| LTM Aug 2026 | $10.37M USD | +26.6% | +8.4% | 1.5% | |
| Peer median (excluding CBT) | — | +13.4% | +6.4% | 5.3% | |
Competitors are the stored peer set for CBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 3.41B | 4.32B | 3.93B | 3.99B | 3.71B |
| Cost of Revenue | 2.61B | 3.44B | 3.09B | 3.03B | 2.77B |
| Gross Profit | 799M | 885M | 839M | 960M | 940M |
| Gross Margin | 23.4% | 20.5% | 21.3% | 24.0% | 25.3% |
| Research & Development | 56M | 55M | 57M | 63M | 59M |
| Selling, General & Admin | 289M | 258M | 253M | 283M | 260M |
| Operating Expenses | 345M | 496M | 313M | 346M | 319M |
| Depreciation & Amortization | 160M | 146M | 144M | 151M | 154M |
| EBITDA | 615M | 537M | 685M | 761M | 794M |
| EBITDA Margin | 18.0% | 12.4% | 17.4% | 19.1% | 21.4% |
| Operating Income | 454M | 389M | 526M | 614M | 621M |
| Operating Margin | 13.3% | 9.0% | 13.4% | 15.4% | 16.7% |
| Interest Income | 8M | 11M | 31M | 32M | 27M |
| Interest Expense | 49M | 56M | 90M | 81M | 76M |
| Other Income / Expenses | (45M) | (44M) | (70M) | (79M) | (49M) |
| Income Before Tax | 409M | 345M | 456M | 535M | 572M |
| Pre-Tax Margin | 12.0% | 8.0% | 11.6% | 13.4% | 15.4% |
| Income Tax Expense | 123M | 102M | (28M) | 111M | 196M |
| Net Income | 250M | 209M | 445M | 380M | 331M |
| Net Margin | 7.3% | 4.8% | 11.3% | 9.5% | 8.9% |
| EPS (Basic) | 4.36 | 3.65 | 7.79 | 6.79 | 6.07 |
| EPS (Diluted) | 4.34 | 3.62 | 7.73 | 6.72 | 6.02 |
| Weighted Avg Shares | 56.73M | 56.25M | 55.24M | 54.3M | 53.7M |
| Weighted Avg Shares (Diluted) | 56.8M | 56.9M | 56.5M | 55.7M | 54.2M |
Cabot Corporation
NYSE:CBT
Intrinsic Alpha fair value
Locked
Current Price
$74.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.